[HTML] frontiersin.org

[HTML][HTML] Overcoming tumor resistance mechanisms in CAR-NK cell therapy

A Valeri, A García-Ortiz, E Castellano… - Frontiers in …, 2022 - frontiersin.org
Despite the impressive results of autologous CAR-T cell therapy in refractory B
lymphoproliferative diseases, CAR-NK immunotherapy emerges as a safer, faster, and cost …
被引用次数：40 相关文章

Overcoming tumor resistance mechanisms in CAR-NK cell therapy

A Valeri, A García-Ortiz, E Castellano… - Frontiers in …, 2022 - pubmed.ncbi.nlm.nih.gov
Despite the impressive results of autologous CAR-T cell therapy in refractory B
lymphoproliferative diseases, CAR-NK immunotherapy emerges as a safer, faster, and cost …
[HTML] nih.gov

[HTML][HTML] Overcoming tumor resistance mechanisms in CAR-NK cell therapy

A Valeri, A García-Ortiz, E Castellano… - Frontiers in …, 2022 - ncbi.nlm.nih.gov
Despite the impressive results of autologous CAR-T cell therapy in refractory B
lymphoproliferative diseases, CAR-NK immunotherapy emerges as a safer, faster, and cost …

Overcoming tumor resistance mechanisms in CAR-NK cell therapy.

A Valeri, A García-Ortiz, E Castellano… - Frontiers in …, 2022 - europepmc.org
Despite the impressive results of autologous CAR-T cell therapy in refractory B
lymphoproliferative diseases, CAR-NK immunotherapy emerges as a safer, faster, and cost …

Overcoming tumor resistance mechanisms in CAR-NK cell therapy.

A Valeri, A García-Ortiz, E Castellano… - Frontiers in …, 2022 - europepmc.org
Despite the impressive results of autologous CAR-T cell therapy in refractory B
lymphoproliferative diseases, CAR-NK immunotherapy emerges as a safer, faster, and cost …